Last update July 3, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Modafinil belongs to this group or family:
Main tradenames from several countries containing Modafinil in its composition:
|Tmax||2 - 4||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Central stimulant, selective inhibitor of dopamine and norepinephrine reuptake. Modafinil is a racemic mixture of its R enantiomer and its S enantiomer. The R enantiomer, known as armodafinil, is pharmacologically active, while the S enantiomer is inactive (Aurora 2018). Used in narcolepsy. Oral administration in one or two daily doses.
Modafinil is excreted in breastmilk in clinically insignificant amounts (Aurora 2018) and no problems have been observed in six infants whose mothers were taking modafinil. (Calvo 2018)
Modafinil can reduce prolactin levels. (Samuels 2006)
A mother reported to us in 2020 nervousness and sleeping difficulties in her breastfed daughters, which forced her to suspend treatment (age of girls and doses unspecified).
Until there is further published data on this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in cases of prematurity.
See below the information of these related products: